Treatment of dyslipoproteinaemia in diabetes mellitus

Diabetic Medicine

Volumn 13, Issue 4, 1996, Pages 297-312

  Dean, J D ^a   Durrington, P N ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Bile acid sequenstrating agents; Cholesterol; Coronary heart disease; Diabetes mellitus; Dyslipoproteinaemia; Fibric acid derivatives; High density lipoprotein; Hyperlipoproteinaemia; Statins; Triglycerides

Indexed keywords

ACIPIMOX; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BEZAFIBRATE; CHOLESTEROL; COLESTIPOL; COLESTYRAMINE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLIBENCLAMIDE; GUAR GUM; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; METFORMIN; MEVINOLIN; NICOTINIC ACID DERIVATIVE; OMEGA 3 FATTY ACID; PROBUCOL; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

AGE; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET; DRUG EFFECT; DYSLIPOPROTEINEMIA; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; KIDNEY DISEASE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ADMINISTRATION, ORAL; ANTILIPEMIC AGENTS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYPERLIPOPROTEINEMIAS; HYPOGLYCEMIC AGENTS; MALE; RISK FACTORS;

EID: 0029972654     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199604)13:4<297::AID-DIA82>3.0.CO;2-Q     Document Type: Review

References (187)

1. Alberti KGMM, Gries FA. Management of non-insulin dependent diabetes mellitus in Europe. A consensus view. Diabetic Med 1988; 5: 275-281.
2. European IDDM Policy Group. Consensus guidelines for the management of insulin-dependent (Type 1) diabetes. Diabetes Med 1993; 10: 990-1005.
3. Consensus Statement. Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 1989; 12: 573-579.
4. Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis. An epidemiological view. Diabetes Metab Rev 1987; 3: 463-528.
5. Stamler J, Vaccaro O, Neaton JD, Westworth D. Diabetes and other risk factors and 12 year cardiovascular mortality from men screened for the multiple risk factor intervention trial. Diabetes Care 1993; 16: 434-444.
6. Jarrett RJ, McCartney P, Keen H. The Bedford study. Ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls, and the risk of coronary heart disease in borderline diabetes. Diabetologia 1982; 22: 79-84.
7. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors. The Framingham study. Circulation 1979; 59: 8-13.
8. Barrett EL, Connor EL, Cohn BA, Wingard DL, Echelstein SL. Why is diabetes mellitus a stronger risk factor for fatal ischaemic heart disease in women than in men? The Rancho Bernado study. JAMA 1991; 265: 627-631.
9. Rosengren A, Welin L, Tsipogianni A, Wilhelman L. Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men. A general population study. Br Med J 1989; 299: 1127-1131.
10. Fontbonne A, Eschwege E, Cambien F, Richard JL, Ducimetiere P, Thibult N, et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11 year follow-up of the Paris Prospective Study. Diabetologia 1989; 32: 300-304.
11. Morrish NJ, Steven LK, Head J, Fuller JH, Jarrett RJ, Keen H. A prospective study of mortality among middle aged diabetic patients (the London cohort of the WHO multinational study of vascular disease in diabetics). II: associated risk factors. Diabetologia 1990; 33: 542-548.
12. Janka HU. Five year incidence of major macrovascular complications in diabetes mellitus. Horm Metab Res 1985: suppl 15: 15-19.
13. Usitupa MIJ, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K. Ten year incidence of cardiovascular mortality in relation to risk factors and abnormalities of lipoprotein composition in type 2 (non-insulin-dependent) diabetes and non diabetic subjects. Diabetologia 1993; 36: 1175-1184.
14. West KM, Ahuja MMS, Bennett PH, Czyzyk A, Acosta OMD, Fuller JH, et al. The role of circulating glucose and triglyceride concentrations and their interactions with other risk factors as determinants of arterial disease in nine diabetic population samples from the WHO multinational study. Diabetes Care 1983; 6: 361-369.
15. Assmann G, Schulte H. Relation of HDL-cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (The PROCAM experience). Am J Cardiol 1992; 70: 733-737.
16. Fuh MMT, Sheih SM. Association of low plasma high density lipoprotein (HDL) cholesterol concentration with documented coronary artery disease in males with non-insulin dependent diabetes mellitus. Horm Metabol Res 1987; 19: 267-270.
17. Beach KW, Strandness DE. Arteriosclerosis obliterans and associated risk factors in insulin-dependent and non-insulin-dependent diabetes. Diabetes 1980; 29: 882-888.
18. Siitonen O, Uusitupa M, Pyorala K, Voutilainen E, Lansimies E. Peripheral arterial disease and its relationship to cardiovascular risk factors in newly diagnosed non-insulin dependent diabetes. Acta Med Scand 1986; 220: 205-212.
19. Reckless JPD, Betteridge DJ, Wu P, Payne B, Galton DJ. High-density and low-density lipoproteins and prevalence of vascular disease in diabetes mellitus. Br Med J 1978; 1: 883-886.
20. Seviour PW, Teal TK, Richmond W, Elkeles RS. Serum lipids, lipoproteins and macrovascular disease in non-insulin dependent diabetes: A possible new approach to prevention. Diabetic Med 1988; 5: 166-171.
21. Welbourne TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979; 2: 154-160.
22. Laakso M, Ronnemaa T, Pyorala K, Veikko K, Puukka P, Penttila I. Atherosclerotic vascular disease and its risk factors in non-insulin-dependent diabetic and non-diabetic subjects in Finland. Diabetes Care 1988; 11: 449-463.
23. Ronnemaa T, Laakso M, Kallio V, Pyorala K, Marniemi J, Puukka P. Serum lipids, lipoproteins, and apolipoproteins and the excessive occurrence of coronary heart disease in non-insulin-dependent diabetic patients. Am J Epidemiol 1990; 130: 632-645.
24. Merrin PK, Feher MD, Elkeles RS. Diabetic macrovascular disease and serum lipids is there a connection? Diabetic Med 1992; 1: 9-14.
25. Winocour PH, Durrington PN, Bhatnagar D, MBewu AD, Ishola M, Mackness I, Arrol S. A cross-sectional elevation of cardiovascular risk factors in coronary heart disease associated with type I (insulin-dependent) diabetes mellitus. Diab Res Clin Pract 1992; 18: 187-184.
26. Gordon T, Castelli WP, Hjortland C, Kannel WB, Dawber TR. Diabetes, blood lipids and the role of obesity in coronary heart disease risk for women. Ann Int Med 1977; 87: 393-397.
27. Keen H, Jarrett RJ. The WHO multinational study of vascular disease in diabetes 2. Macrovascular disease prevalence. Diabetes Care 1979; 2: 187-195.
28. Laakso M, Kesaniemi A, Kervinen K, Jauhainen M, Pyorala K. Relation of coronary heart disease and apolipoprotein E phenotype in patients with non-insulin dependent diabetes. Br Med J 1991; 303: 1159-1162.
29. Durrington PN. Hyperlipidaemia. Diagnosis and Management, 2nd edn. Oxford: Butterworth Heinemann, 1995.
30. Koskinen P, Manttari M, Manninen V, Huttenen JK, Heinonon OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992; 15: 820-825.
31. Pyorala K, Pedersen TJ, Kjerkshus J. The effect of cholesterol lowering with Simvastatin on coronary events in diabetic patients with coronary heart disease. Diabetes 1995; 44 (suppl 1): 35A.
32. Davey-Smith G, Song F, Sheldon T. Cholesterol lowering and mortality, the importance of considering initial level of risk. Br Med J 1993; 306: 1367-1373.
33. Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. Br Med J 1994; 308: 373-379.
34. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease. Br Med J 1994; 308: 367-373.
35. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin survival study (4S). Lancet 1994; 344: 1383-1389.
36. Durrington PN. Prevention of macrovascular disease. Absolute proof or absolute risk. Diabetic Med 1995; 12: 561-562.
37. Dean JD. Lipoprotein metabolism and macrovascular disease in NIDDM. MD thesis, Leicester University, 1993.
38. Friedewald WT, Levy RI, Fredrickson DS. Concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
39. Winocour PH, Ishola M, Durrington PN. Validation of the Friedewald formula for the measurement of low density lipoprotein cholesterol in insulin-dependent diabetes mellitus. Clin Chim Acta 1989; 179: 79-84.
40. Sosenko JM, Breslow JL, Miettenen OS, Gabbay KH. Hyperglycaemia and plasma lipid levels. A prospective study of young insulin-dependent diabetic patients. N Engl J Med 1980; 302: 650-654.
41. Winocour PH, Durrington PN, Ishola M, Anderson DC. Lipoprotein abnormalities in insulin dependent diabetes mellitus. Lancet 1986; 1: 1176-1178.
42. The DCCT Research Group. Lipid and lipoprotein levels in patients with IDDM, diabetes control and complications trial experience. Diabetes Care 1992; 15: 886-894.
43. Winocour PH, Durrington PN, Bhatnagar D, Ishola M, Arrol S, Mackness M. Abnormalities of VLDL, IDL, and LDL characterise insulin dependent diabetes mellitus. Arteriosclerosis and Thrombosis 1992; 12: 920-928.
44. Rivallese A, Riccardi G, Romano G, Giaccio R, Piatti L, Marrott G, et al. Presence of very low density lipoprotein abnormalities in type 1 diabetic patients, effects of insulin optimisation. Diabetologia 1988; 31: 884-888.
45. Durrington PN. Serum high density lipoprotein cholesterol in diabetes mellitus: an analysis of factors which influence its concentration. Clin Chim Acta 1980; 104: 11-23.
46. Winocour PH, Durrington PN, Ishola M, Anderson DC, Cohen H. Influence of proteinuria on vascular disease blood pressure and lipoproteins in insulin dependent diabetes. Br Med J 1987; 294: 1648-1651.
47. Short CD, Durrington PN. Hyperlipidaemia and renal disease. Bailliere's Clin End Metab 1990; 4: 777-806.
48. Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res 1987; 28: 613-628.
49. Uusitupa M, Siitonen O, Voutilainen E, Aro A, Hersio K, Pyolara K., et al. Serum lipids and lipoproteins in newly diagnosed non-insulin dependent (type II) diabetic patients, with special reference to factors influencing HDL cholesterol levels and triglyceride levels. Diabetes Care 1986; 9: 17-22.
50. Dean JD, Owens DR, Matthews SB. Apolipoprotein and lipid ratios in non-insulin dependent diabetics. Diabetes Research 1991; 15: 21-25.
51. Facchini FS, Hollenbeck CB, Jeppesen J, Chen YDI, Reaven GM. Insulin resistance and cigarette smoking. Lancet 1992; 339: 1128-1130.
52. Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: analysis of published data. Br Med J 1989; 298: 784-788.
53. Martin JV, Hague RV, Martin PJ, Cullen DR, Goldberg DM. The association between serum triglycerides and gamma glutamyl transpeptidase activity in diabetes mellitus. Clin Biochem 1976; 9: 208-211.
54. Glueck CJ, Levi RI, Fredrickson DS. Immunoreactive insulin, glucose tolerance and carbohydrate inducibility in type II, III, IV, and V hyperlipoproteinaemias. Diabetes 1969; 18: 739-751.
55. Brunzell JD, Hazzard WR, Motulsky AG, Bierman EL. Evidence for diabetes mellitus and genetic forms of hypertriglyceridaemia as independent entities. Metabolism 1975; 24: 1115-1121.
56. Howard BV, Savage PJ, Nagulesparan M, Bennion L, Davis M, Bennett PH. Changes in plasma lipoproteins accompanying diet therapy in obese diabetics. Atherosclerosis 1979; 33: 445-456.
57. Hughes TA, Gwynne JT, Switzer BR, Herbert C, White G. Effects of caloric restriction and weight loss on glycaemic control, insulin release and resistance, and atherosclerotic risk in obese patients with type II diabetes mellitus. Am J Med 1984; 77: 7-17.
58. Henry RR, Wallace P, Olefsky JM. Effects of weight loss on mechanisms of hyperglycaemia in obese non-insulin-dependent-diabetes mellitus. Diabetes 1986; 35: 990-998.
59. Ginsberg H, Grundy S. Very low density lipoprotein metabolism in non-ketotic diabetes mellitus; effects of dietary restriction. Diabetologia 1982; 23: 421-425.
60. Kennedy L, Walshe K, Hadden DR, Weaver JA, Buchanan KD. The effect of intensified dietary therapy on serum high density lipoprotein cholesterol in patients with type 2 (non-insulin-dependent) diabetes mellitus: A prospective study. Diabetologia 1982; 23: 24-27.
61. Taylor KG, John WG, Matthews KA, Wright AD. A prospective study of the effect of 12 months treatment on serum lipids and apolipoprotein A1 and B in type 2 (non-insulin-dependent) diabetes. Diabetologia 1982; 23: 507-510.
62. Wales JK. Treatment of type 2 (non-insulin-dependent) diabetic patients with diet alone. Diabetologia 1982; 23: 240-245.
63. Weisweiler P, Drosner M, Scwandt P. Dietary effects on very low density lipoprotein in type 2 (non-insulin dependent) diabetes mellitus. Diabetologia 1982; 23: 101-104.
64. Liu GC, Coulston AM, Lardinois CK, Hollenbeck CB, Moore JG, Reaven GM. Moderate weight loss and sulphonylurea treatment of non-insulin-dependent diabetes mellitus. Arch Int Med 1985; 145: 665-669.
65. Durrington PN. Dietary fat and coronary heart disease. In: Poulter N, Sever P, Thom S, eds. Cardiovascular Disease. Risk factors and Intervention. Oxford: Radcliffe Medical Press, 1993: 119-128.
66. Grundy SM. Dietary therapy of hyperlipidaemia. Ballière's Clin End Metab 1987; 1: 667-698.
67. Hockaday TDR, Hockaday JM, Mann JI, Turner RC. Prospective comparison of modified-fat-high-carbohydrate with standard low-carbohydrate dietary advice in the treatment of diabetes: One year follow up study. Br J Nutr 1978; 39: 357-362.
68. Simpson RW, Mann JI, Hockaday TDR, Hockaday JM, Turner RC, Jeffs R. Lipid abnormalities in untreated maturity onset diabetes and the effect of treatment. Diabetologia 1979; 16: 101-106.
69. Abbott WGH, Boyce VL, Grundy S, Howard BV. Effects of replacing standard fat with complex carbohydrate in diets of subjects with NIDDM. Diabetes Care 1989: 12: 102-1007.
70. Anderson JW, Chien W-JL, Sieling B. Hypolipidaemic effects of high carbohydrate, high fibre diets. Metabolism 1980; 29: 551-557.
71. Simpson HCR, Simpson RW, Lousey S, Carter RD, Griekie M, Hockaday TDR, Mann JI. A high carbohydrate leguminous fibre diet improves all aspects of diabetic control. Lancet 1981; i: 1-5.
72. Riccardi G, Rivallese A, Pacioni D, Genovese S, Mastranzo P, Mancini M. Separate influence of dietary carbohydrate and fibre on metabolic control in diabetes. Diabetologia 1984; 26: 116-121.
73. Coulston AM, Hollenbeck CB, Swisloki AL, Reaven GM. Persistence of hypertriglyceridaemic effect of low fat high-carbohydrate diets in NIDDM patients. Diabetes Care 1989; 12: 94-101.
74. Garg A, Bonanome A, Grundy SM, Zhang Z-J, Unger RH. Comparison of a high-carbohydrate diet with a high-monounsaturated fat diet in patients with non-insulin-dependent diabetes mellitus. New Engl J Med 1988; 319: 829-834.
75. Garg A, Grundy SM, Unger RH. Comparison of effects of high and low carbohydrate diets on plasma lipoproteins and insulin sensitivity in patients with mild NIDDM. Diabetes 1992; 41 1278-1285.
76. Garg A, Grundy SM, Koffler M. Effect of high carbohydrate intake on hyperglycaemia, islet function and plasma lipoproteins in NIDDM. Diabetes Care 1992; 15: 1572-1580.
77. Anderson JW, Akanji AO. Dietary fibre - an overview. Diabetes Care 1991; 14: 1126-1131.
78. O'Dea K, Traianedes K, Ireland P, Niall M, Sadler J, Hopper J, De Luise M. The effects of differing in fat, carbohydrate and lipid metabolism in type II diabetes. J Am Diet Assoc 1989; 89: 1076-1086.
79. Riccardi G, Rivellese AA. Effects of dietary fibre and carbohydrate on glucose and lipoprotein metabolism in diabetic patients. Diabetes Care 1991; 14: 1115-1125.
80. British Diabetic Association Nutrition Subcommittee. Dietary recommendations for people with diabetes: An update for the 1990s. Diabetic Med 1992; 9: 189-202.
81. American Diabetes Association. Position statement: diabetes and exercise. Diabetes Care 1990; 13: 805.
82. Schneider SH, Vitug A, Ruderman N. Atherosclerosis and physical activity. Diabetes/Metabolism Reviews 1966; 1: 513-553.
83. Lampman RM, Schteingart DE, Santiga JT, Savage PJ, Hydrick CR, Basset, DR, Block WD. The influence of physical training on glucose tolerance, insulin sensitivity and lipid and lipoprotein concentrations in middle aged hypertriglyceridaemic carbohydrate intolerant men. Diabetologia 1987: 30: 380-385.
84. Ronnemaa T, Marniemi J, Punkka P, Kuusi T. Effects of long term physical exercise on serum lipids, lipoproteins and lipid metabolising enzymes in type 2 (non-insulin-dependent) diabetic patients. Diabetes Res 1988; 7: 79-84.
85. Schneider SH, Khachadurian AK, Amorosa LF, Clemow L, Ruderman NB. Ten year experience with an exercise based outpatient life style modification program in the treatment of diabetes mellitus. Diabetes Care 1992; 15: 1800-1806.
86. Morris JH, West DA, Bolinger RE. Effect of sulphonyfurea on plasma triglycerides in diabetics. Diabetes 1964; 13: 87-89.
87. Paisey R, Elkeles RS, Hambey J, Magill P. The effects of chlorpropamide and insulin on serum lipids, lipoproteins and fractional triglyceride removal. Diabetologia 1978; 15: 81-85.
88. Simpson RW, Mann JI, Hockaday TDR, Hockaday JM, Turner RC, Jeffs R. Lipid abnormalities in untreated maturity onset diabetes and the effect of treatment. Diabetologia 1979; 16: 101-106.
89. Greenfield MS, Doberne L, Rosenthal M, Vrenau HJ, Reaven GM. Lipid metabolism in non-insulin dependent diabetes mellitus. Effect of glipizide therapy. Arch Intern Med 1982; 142: 1298-1500.
90. Pfeifer MA, Brunzell JD, Best JD, Judewitsch RG, Halten JB, Porte D. The response of plasma triglyceride, cholesterol and lipoprotein lipase to treatment in non-insulin-dependent diabetic subjects without familial hypertriglyceridaemia. Diabetes 1983; 32: 525-531.
91. Liu GC, Coulston AM, Lardinois CK, Hollenbeck CB, Moore JG, Reaven GM. Moderatae weight loss and sulphonylurea treatment of non-insulin-dependent diabetes mellitus. Arch Int Med 1985; 145: 665-669.
92. Taskinen M-R, Beltz WF, Harper I, Schofeld G, Grundy S, Howard BV. Effects of NIDDM on very low density lipoprotein triglyceride and apolipoprotein B metabolism. Studies before and after sulphonylurea therapy. Diabetes 1986; 35: 1268-1277.
93. Maruhama Y, Takahashi K, Hasimoto T. Treatment of atherogenic dyslipoproteinaemia in NIDDM through strict glycaemic control using sulphonylureas. In: N. Sakamoto, KGMM Alberti, N Hotta, eds. Recent Trends in Management of Diabetes Mellitus. Elsevier, Amsterdam 1987.
94. Nathan DM, Roussell A, Godine JE. Gliburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus. A randomised double blind study. Ann Int Med 1988; 108: 334-340.
95. Taskinen M-R, Harno K, Nikkila EA. Serum lipids and lipoproteins in type 2 diabetes. Acta End Suppl 1984; 262: 95-99.
96. Bergman M, Gidez LI, Eder HA. The effect of Glipizide on HDL and HDL subclasses. Diabetes Res 1986; 3: 245-248.
97. Rains SGH, Witson GA, Richmond W, Elkeles RS. The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes. Diabetic Med 1988; 5: 653-658.
98. Taskinen M-R. Lipoprotein lipase in diabetes. Diabetes Metabolism Reviews 1987; 3: 551-570.
99. Kennedy L, Lappin TRG, Lavery TD, Hadden DR, Weaver JA, Montgomery DAD. Relation of high-density lipoprotein cholesterol concentration to type of diabetes and its control. Br Med J 1978; 2: 1191-1194.
100. Calvert GD, Graham JJ, Mannick T, Wise PH, Yeates RA. Effects of therapy on plasma high density lipoprotein cholesterol concentrations in diabetes mellitus. Lancet 1978; ii: 66-68.
101. Lisch H-J, Sailer S. Lipoprotein patterns in diet sulphonylurea and insulin treated diabetics. Diabetologia 1981; 20: 118-122.
102. Schneider J, Erren T, Zofel P, Kaffarnik H. Metformin induced changes in serum lipids, lipoproteins, and apolipoproteins in non-insulin-dependent diabetes mellitus. Atherosclerosis 1990; 82: 97-103.
103. Wu M-S, Johnston P, Shen WH-H, Hollenbeck CB, Jeng C-Y, Chen Y-D, Reaven GM. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 1990; 13: 1-8.
104. Lalor BC, Bhatnagar D, Ishola M, Arrol S, Brading M, Durrington PN. Placebo controlled trial of the effects of guar gum and metformin on fasting blood glucose and serum lipids in obese type 2 diabetic patients. Diabetic Med 1989; 7: 242-245.
105. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care 1993; 16: 621-629.
106. Sirtori CR, Tremoli E, Sirtori M, Conti F, Paoletti R. Treatment of hypertriglyceridaemia with metformin. Atherosclerosis 1977; 26: 583-592.
107. Landin KI, Tengborn L, Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med 1991; 229: 181-187.
108. Gingliano D, Rosa ND, Maro GD, Marfella R, Acampora R, Buonincontis R, et al. Metformin improves glucose, lipid, metabolism and reduces blood pressure in hypertensive obese women. Diabetes Care 1993; 16: 1387-1390.
109. Rains SGH, Wilson GA, Richmond W, Elkeles RS. The reduction of low density lipoprotein cholesterol by metformin is maintained with long term therapy. J Roy Soc Med 1989; 82: 93-94.
110. Chan JCN, Tomlinson B, Critchley JAJH, Cockram CS, Walden RJ. Metabolic and haemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients. Diabetes Care 1993; 16: 1035-1038.
111. Hanefeld M, Fischer S, Sculze J, Spengler M, Wargenave M, Scollberg K, Fucker, K. Therapeutic potential of acarbose as first line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 1991; 14: 732-737.
112. Balfour JA, McTavish D, Acarbose. An update of its pharmacological and therapeutic use in Diabetes mellitus. Drugs 1993; 46: 1025-1054.
113. Feusell HS, Williams G, Adrian TE, Bloom SR. Guar sprinkled on food: effect on glycaemic control, plasma lipids and gut hormones in non-insulin dependent diabetic patients. Diabetic Med 1987; 4: 463-468.
114. Aro A, Uusitupa M, Voutilainen E, Korhonen T, Siitonen O. Improved diabetic control and hypocholesterolaemic effect by long term dietary supplementation with guar gum in type 2 (insulin independent) diabetes. Diabetologia 1981; 21: 29-33.
115. Hermann LS, Karlsson JE, Sjostrand A. Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles. Eur J Clin Pharmacol 1991; 41: 263-265.
116. Lopes-Virella MF, Wohltmann HJ, Mayfield RK, Colwell JA. Effect of metabolic control on lipid, lipoprotein and apolipoprotein levels in 55 insulin dependent diabetic patients. A longitudinal study. Diabetes 1983; 32: 20-25.
117. Dunn FL, Pietri A, Raskin P. Plasma lipid and lipoprotein levels with continuous subcutaneous insulin infusion in type 1 diabetes mellitus. Ann Intern Med 1981; 95: 426-431.
118. Georgopolous A, Saudek CD. Normalization of composition of triglyceride rich lipoprotein subfractions in diabetic patients during insulin infusion with programmable implantable medication system. Diabetes Care 1992; 15: 19-26.
119. Ruotolo G, Parlavecchia M, Taskinen MR, Galimberti G, Zoppo A, Le NA, et al. Normalization of lipoprotein composition by intraperitoneal insulin in IDDM. Role of increased hepatic lipase activity. Diabetes Care 1994; 17: 6-12.
120. Taskinen M-R, Kuusi T, Helve E, Nikkila EA, Yki-Jarvinen H. Insulin therapy induces antiatherogenic changes of serum lipoproteins in non-insulin-dependent diabetes. Arteriosclerosis 1988; 8: 168-177.
121. Rabkin SW, Boyko E, Streja DA. Changes in high density lipoprotein cholesterol after initiation of insulin therapy in non-insulin dependent diabetes mellitus: relationship to change in body weight. Am J Med Sci 1983; 285: 14-20.
122. Hollenbeck CB, Chen Y-DA, Greenfield MS, Lardinois CK, Reaven GM. Reduced plasma high density lipoprotein cholesterol concentration need not increase when hyperglycaemia is controlled with insulin in non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1986; 62: 605-608.
123. Agardh C-D, Nilsson-Ehle P, Schernsten B. Improvement of plasma lipoprotein pattern after initiation of insulin treatment in diabetes mellitus. Diabetes Care 1982; 5: 322-325.
124. Hughes TA, Clements RS, Fairclough PK, Ball DSH, Segrest JP. Effect of insulin therapy on lipoproteins in non-insulin dependent diabetes mellitus (NIDDM). Atherosclerosis 1987; 67: 105-114.
125. Abrams JJ, Ginsberg H, Grundy S, Metabolism of cholesterol and plasma triglycerides in non-ketotic diabetes mellitus. Diabetes 1982; 31: 903-910.
126. Schmitt JK, Harriman K, Poole JR. Modification of therapy from insulin to chlorpropamide decreases HDL cholesterol in patients with non-insulin-dependent diabetes mellitus. Diabetes Care 1987; 10: 692-696.
127. Nathan DM, Roussell A, Godine JE. Gliburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus. A randomised double blind study. Ann Int Med 1988; 108: 334-340.
128. Lindstrom T, Arnqvist HJ, Olsson AG. Effect of different insulin regimens on plasma lipoprotein and apolipoprotein concentrations in patients with non-insulin dependent diabetes mellitus. Atherosclerosis 1990; 81: 137-144.
129. Yki Jarvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, et al. Comparison of insulin regimens in patients with non-insulin dependent diabetes mellitus. New Engl J Med 1992; 327: 1426-1433.
130. Groop LC, Widen E, Ekstrand A, Saloranta C, Franssila Kallunki A, et al. Morning or bedtime NPH insulin combined with sulphonylurea in treatment of NIDDM. Diabetes Care 1992; 15: 831-834.
131. Giugliano D, Quatraro A, Consoli G, Mineri A, Ceriello A, De Rosa N, D'Onofrio F. Metformin for obese, insulin treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 1993; 44: 107-112.
132. Vinik AI, Colwell JA. Effects of gemfibrozil on triglyceride levels in patients with NIDDM. Diabetes Care 1993; 16: 37-44.
133. Lahdenpera S, Tilly-Kiesi M, Vuorinen-Markkola H, Kuusi T, Taskinen MR. Effects of Gemfibrozil on low-density lipoprotein particle size, density distribution and composition in patients with type 2 diabetes. Diabetes Care 1993; 584-592.
134. Garg A, Grundy SM, Gemfibrozil alone and in combination with Lovastatin for treatment of hypertriglyceridaemia in NIDDM. Diabetes 1989; 38: 364-372.
135. Kahri J, Vuorinen-Markkola H, Tilly-Kiesi M, Lahdenpera S, Kuusi T, Taskinen MR. Effect of gemfibrozil on high density lipoprotein subspecies in non-insulin dependent diabetes mellitus: relations to lipolytic enzymes and to the cholesterol ester transfer protein activity. Atherosclerosis 1993; 102: 79-89.
136. Mathur S, Barradas MA, Mikhailidis DP, Dandona P. The effect of a slow release formulation of bezafibrate on lipids, glucose homeostasis, platelets and fibrinogen in type II diabetics: A pilot study. Diabetes Res 1990; 14: 133-138.
137. Prager R, Scernthaner G, Kostner GM, Mulhauser I, Zechener R, Dorda W. Effect of bezafibrate on plasma lipids, lipoproteins, apolipoproteins AI, AII and B, and LCAT activity in hyperlipidaemic non-insulin dependent diabetics. Atherosclerosis 1982; 43: 321-327.
138. Jones IR, Swai A, Taylor R, Miller M, Laker MF, Alberti KGMM. Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM. Diabetes Care 1990; 13: 855-863.
139. Kobayashi M, Shigeta Y, Hirsta Y, Omori Y, Skamoto N, Nambu S, Baba S. Improvement of glucose tolerance in NIDDM by Clofibrate. Randomised double-blind study. Diabetes Care 1988; 11: 495-499.
140. Harig HU, Schleicher E, Renner R, Mehnert H. The effect of fenofibrate on lipid levels in diabetics. Therapaeutisce Mitteilung 1983; 125: 751-753.
141. Smud R, Sermukslis B. Bezafibrate and fenofibrate in Type II diabetics with hyperlipoproteinaemia. Curr Med Res Opin 1987; 10: 612-623.
142. Marks J, Howard AN. A comparative study of gemfibrozil and clofibrate in the treatment of hyperlipidaemia in patients with maturity onset diabetes. Res Clin Forums 1982; 4: 96-103.
143. Barnett D, Craig JG, Robinson DS, Rogers MP. Effect of clofibrate on glucose tolerance in maturity onset diabetes. Br J Clin Pharmacol 1977; 4: 455-458.
144. Winocour PH, Durrington PN, Bhatnagar D, Ishola M, Arrol S, Lalor BC, et al. Double-blind placebo controlled study of the effects of bezafibrate on blood lipids, lipoproteins and fibrinogen in hyperlipidaemic type 1 diabetes mellitus. Diabetic Med 1990; 7: 736-743.
145. Schade DS, Eaton RP, George S, Conway M, Kaminski N, Sivinski J. Metabolic effects of clofibrate in insulin-dependent ketosis-prone diabetic man. Metabolism 1978; 27: 461-468.
146. Garg A, Grundy SM. Lovastatin for lowering cholesterol in non-insulin dependent diabetes mellitus. New Engl J Med 1988; 318: 81-86.
147. Bhatnagar D, Durrington PN, Kumar S, Mackness MI, Dean J, Boulton AJM. Effect of treatment with a hydroxymethylglutaryl coenzyme A reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester transfer activity in patients with NIDDM. Diabetes 1995; 44: 460-465.
148. Steyn K, Weich HFN, Bonnici F, Kotze TJVW, Stander I, Vermaak WJH, et al. Simvastatin in non-insulin-dependent diabetic patients with hypercholesterolaemia. South African Med J 1992; 82: 402-406.
149. Cassader M, Ruiu G, Gambino R, Alemanno N, Veglia F, Pagano G. Hypercholesterolemia in non-insulin-dependent diabetes mellitus: different effect of simvastatin on VLDL and LDL cholesterol levels. Atherosclerosis 1993; 99: 47-53.
150. Stewart MW, Dyer RG, Alberti KGMM, Laker MF. The effects of lipid-lowering drugs on metabolic control and lipoprotein composition in type 2 diabetic patients with mild hyperlipidaemia. Diabetic Med 1995; 12: 250-257.
151. Hommel E, Andersen P, Gall MA, Nielsen F, Jensen B, Rossing P, et al. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia 1992; 35: 447-451.
152. Goldberg R, La Belle P, Zupkis R, Ronca P. Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose control in non-insulin dependent diabetes mellitus. Am J Cardiol 1990; 66: 16-21B.
153. Kudchodkar BJ, Sodhi HS, Horlick L, Mason DT. Mechanisms of hypolipidemic action of nicotinic acid. Clin Pharm Ther 1978; 24: 354-373.
154. Gurian H, Aldersber D. The effect of large doses of nicotinic acid on circulating lipids and carbohydrate tolerance. Am J Med Sci 1959; 237: 12-22.
155. Berge K. Side effects of nicotinic acid in treatment of hypercholesterolaemia. Geriatrics 1961; 16: 416-422.
156. Molnar GD, Berge KG, Rosevear JW, McGukin WF, Achor RWP. The effect of nicotinic acid in diabetes mellitus. Metabolism 1963: 13: 181-190.
157. Miettinen TA, Taskinen M-R, Peljonnen R, Nikkila EA. Glucose tolerance and plasma insulin in man during acute and chronic administration of nicotinic acid. Acta Med Scand 1969; 186: 247-253.
158. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidaemia in non-insulin dependent diabetes mellitus. J Am Med Assoc 1990; 264: 723-726.
159. Ball MJ, Vella M, Reckless JPD, Jones DB, Stirling C, Mann JI, Galton D. Acipimox in the treatment of patients with hyperlipidaemia. A double blind trial. Eur J Clin Pharm 1986; 31: 201-204.
160. Dean JD, McCarthy S, Betteridge DJ, Whately-Smith C, Powell J, Owens DR. The effect of acipimox in patients with Type 2 diabetes and persistent hyperlipidaemia. Diabetic Med 1992; 9: 611-615.
161. Fulcher GR, Catalano C, Walker M, Farrer M, Thow J, Whately-Smith CR, et al. A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with Type 2 diabetes mellitus. Diabetic Med 1992; 10: 908-914.
162. Scott RS, Lintott CJ, Bremer JM, Shand B, Sutherland WHF. Improvements in atherogenic risk factors with acipimox in non-insulin dependent diabetic subjects. Atherosclerosis Reviews 1991; 22: 201-206.
163. Koev D, Zlateva S, Susic M, Babic D, Profozic V, Skrabalo Z, et al. Improvement of lipoprotein lipid composition in type II diabetic patients with concomitant hyperlipoproteinaemia by acipimox treatment. Diabetes Care 1993; 16: 1285-1291.
164. Niort G, Cassader M, Gambino R, Pagano G. Comparison of the effects of bezafibrate and acipimox on the lipid pattern and plasma fibrinogen in hyperlipidaemic type 2 (non-insulin-dependent) diabetic patients. Diabete Metabolisme 1992; 18: 221-228.
165. Lees AM, McClusky MA, Lees R. Results of colestipol therapy in type II hyperlipoproteinaemia. Atherosclerosis 1976; 24: 129-140.
166. Garg A, Grundy SM. Cholestyramine therapy for dyslipidaemia in non-insulin dependent diabetes mellitus. A short-term, double-blind crossover trial. Ann Intern Med 1994; 121: 416-422.
167. Bandisode MS, Boschell BR. Hypocholesterolaemic activity of colestipol in diabetes. Curr Ther Res 1975; 18: 276-284.
168. Duntch VG. Langerzeittuerapie der hypercholesterinamie beim diabetiker met colestipol. Fortschr Med 1981; 99: 73-75.
169. Yoshino G, Kazumi T, Uenoyama R, Kasama T, Iwai M, Otuski M, et al. Probucol versus Eptastatin in hypercholesterolaemic diabetics. Lancet 1986; ii: 740-741.
170. Hattori M, Tsuda K, Taminato T, Nishi S, Fujita J, Tsuji K, et al. Effect of Probucol on serum lipids and apolipoprotein in patients with non-insulin dependent diabetes mellitus. Curr Ther Res 1987; 42: 967-973.
171. Schectmann G, Kaul S, Kissebah AH. Effect of fish oil concentrate on lipoprotein composition in NIDDM. Diabetes 1988; 37: 1567-1573.
172. Friday KE, Childs MT, Tsunahara CH, Fujimoto WY, Bierman EL, Ensink JW. Elevated plasma glucose and lowered triglyceride levels from omega 3 fatty acid supplementation in type II diabetes. Diabetes Care 1989; 12: 276-281.
173. Vesby D, Boberg M. Dietary supplementation with n3 fatty acids may impair glucose homeostasis in patients with non insulin dependent diabetes mellitus. J Intern Med 1990; 220: 165-171.
174. Glauber H, Wallace P, Griver K, Brachtal G. Adverse metabolic effect of omega 3 fatty acids in non insulin dependent diabetes mellitus. Ann Intern Med 1988; 100: 663-668.
175. Borsch-Johnsen K, Kreiner S. Proteinuria: value as a predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br Med J 1987; 294: 1651-1654.
176. Vannini P, Giavarella A, Flammini M, Bargossi AM, Forlani G, Borgnino LC, Orsoni G. Lipid abnormalities in insulin dependent diabetic patients with albuminuria. Diabetes Care 1984; 7: 151-154.
177. Groggel GC, Cheung AK, Ellis Benigni K, Wilson DK. Treatment of nephrotic hyperlipoproteinaemia with gemfibrozil. Kidney International 1993; 44: 1124-1129.
178. Thomas ME, Harris KPG, Ramawany C, Hattersley JM, Wheeler DC, Vardhese Z, et al. Simvastatin therapy for hypercholesterolaemic patients with nephrotic syndrome or significant proteinuria. Kidney International 1993; 44: 1124-1129.
179. Warwick GL, Packard CJ, Murray L, Grierson D, Stewart JP, et al. Effect of simvastatin on plasma lipid and lipoprotein concentrations and low-density lipoprotein metabolism in the nephrotic syndrome. Clin Sci 1992; 82: 701-708.
180. Chan MK. Gemfibrozil improves abnormalities of lipid metabolism in patients on CAPD. Metabolism 1989; 38: 939-945.
181. Chan MK. Sustained release bezafibrate corrects lipid abnormalities in patients on continuous ambulatory peritoneal dialysis. Nephron 1990; 56: 56-61.
182. Wanner C, Lubrich I, Suma O, Wieland H, Schollneyer P. Effect of simvastatin on qualitative and quantitative changes of lipoproteins in CAPD patients. Nephron 1992; 62: 40-46.
183. Barzilay JI, Kronmal RA, Bittner V, Eaker E, Evans C, Foster ED. Coronary artery disease and coronary artery bypass grafting in diabetic patients age greater than or equal to 65 years. Am J Cardiol 1994; 74: 334-339.
184. Lynch M, Gammage MD, Lamb P, Natrass M, Pentecost BL. Acute myocardial infarction in diabetic patients in the thrombolytic era. Diabetic Med 1994; 11: 162-165.
185. Martin KA, Freeman MW. Postmenopausal Hormone Replacement Therapy. New Engl J Med 1992; 328: 1115-1116.
186. Pyorala K, De Backer G, Graham I, Poole-Wilson P, Wood D. on behalf of the Task Force. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis 1994; 110: 121-161.
187. Schulte H, Assmann G. CHD risk equations, obtained from the Framingham Heart Study, applied to the PRO-CAM Study. Cardiovasc Risk Factors 1991; 1: 126-133.